Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2010-02-04
2011-12-13
Henley, III, Raymond (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000
Reexamination Certificate
active
08076319
ABSTRACT:
The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose.
REFERENCES:
patent: 4425339 (1984-01-01), Pitchford
patent: 5043331 (1991-08-01), Hirvonen et al.
patent: 5108995 (1992-04-01), Casper
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5827843 (1998-10-01), Koninckx
patent: 5877219 (1999-03-01), Willson
patent: 5891867 (1999-04-01), Lanquetin et al.
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 5935949 (1999-08-01), White
patent: 7427609 (2008-09-01), Leonard
patent: WO 98/06404 (1998-02-01), None
patent: WO 00/74684 (2000-12-01), None
Medline Abstract No. 97217050, Kumar, Indian Journal of Experimental Biology, (May 1996) 34(5), 391-402.
Medline Abstract No. 96432582, Oka et al., Japanese Journal of Pharmacology, (Jun. 1996) 71(2), 89-100.
Medline Abstract No. 97074593, Smith et al., CA: A Cancer Journal for Clinicians, (Nov.-Dec. 1996), 46(6), 343-63.
Simon et al.,Unscheduled Bleeding During Initiation of Continuous Combined Hormone Replacement Therapy: A Direct Comparison of Two Combinations of Norethindrone Acetate and Ethinyl Estradiol to Medroxyprogesterone Acetate and Conjugated Equine Estrogens, Menopause, The Journal of the North American Menopause Society, vol. 8, No. 5. 2001. pp. 321-327.
Pickar et al.,Endometrial Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate. Fertility and Sterility. vol. 76. No. 1. Jul. 2001, pp. 25-31.
Chesnut et al.,A Randomized Trial of Nasal Spray Salmon Calcitonin in Postmenopausal Women With Established Osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study, The American Journal of Medicine, vol. 109. Sep. 2000. pp. 267-276.
Archer et al.,Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate on Endometrial Bleeding. Fertility and Sterility. vol. 75, No. 6. Jun. 2001, pp. 1080-1087.
Dawson et al.,A Randomized Study Comparing Standard Versus Moderately High Dose Megestrol Acetate for Patients With Advanced Prostate Carcinoma Cancervol. 88, No. 4, Feb. 15, 2000, pp. 825-834.
Farinha et al.,Improved Bioavailability of a Micronized Megestrol Acetate Tablet Formulation in Humans, Drug Development and Industrial Pharmacy, vol. 26, No. 5, 2000, pp. 567-570.
Naing et al.,Megestrol Acetate Therapy and Secondary Adrenal Suppression, Cancer, vol. 86, No. 6, Sep. 15, 1999, pp. 1044-1049.
Bernhard et al.,Quality of Life in Postmenopausal Patients With Breast Cancer After Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-Line Hormonal Treatment, European Journal of Cancer. vol. 35, No. 6, 1999, pp. 913-920.
Loprinzi et al.,Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia, Journal of Clinical Oncology, vol. 17, No. 10, Oct. 1999, pp. 3299-3306.
Engelson et al.,Effects of Megestrol Acetate and Testosterone on Body Composition in Castrated Male Sprague-Dawley Rats, Nutrition. vol. 15, No. 6, 1999, pp. 465-473.
Critchley et al.,Effects of Estrogen and Progesterone on the Endometrium, Estrogens and Progestagens in Clinical Practice, edited by Fraser et al., 1998, pp. 145-161.
Ross et al.,Endometrial Effects of Three Doses of Trimegestone a New Orally Active Progestogen, On the Postmenopausal Endometrium. Maturitas, vol. 28. 1997. pp. 83-88.
Conard et al.,Cardiovascular Risk Factors and Combined Estrogen-Progestin Replacement Therapy: A Placebo-Controlled Study With Nomegestrol Acetate and Estradiol, Fertility and Sterility, vol. 64, No. 5, Nov. 1995, pp. 957-962.
Sturdee et al.,Is the Timing of Withdrawal Bleeding a Guide to Endometrial Safety During Sequential Oestrogen-Progestagen Replacement Therapy?, The Lancet, vol. 334, Oct. 8, 1994, pp. 979-982.
Von Rocnn,Randomized Trials of Megestrol Acetate for AIDS-Associated Anorexia and Cachexia, Oncology, vol. 51, Suppl 1. 1994, 19-24.
Espie,Megestrol Acetate in Advanced Breast Carcinoma, Oncology, vol. 51, Suppl 1, 1994, pp. 8-12.
Loprinzi et al.,Megestrol Acetate for the Prevention of Hot Flashes, The New England Journal of Medicine, vol. 331. No. 6, Aug. 11, 1994, pp. 347-352.
Sporrong et al.,A Novel Statistical Approach to Analysis of Bleeding Patterns During Continuous Hormone Replacement Therapy. Maturitas, vol. 11, 1989, pp. 209-215.
Schacter et al.,Megestrol Acetate: Clinical Experience, Cancer Treatment Reviews, vol. 16, 1989, pp. 49-63.
Sporrong et al.,Comparison of Four Continuously Administered Progestogen Plus Oestradiol Combinations for Climacteric Complaints, British Journal of Obstetrics and Gynaecology, vol. 95, Oct. 1988, pp. 1042-1048.
Alexieva-Figusch et al.,Treatment of Metastatic Breast Cancer Patients With Different Dosages of Megestrol Acetate; Dose Relations, Metabolic and Endocrine Effects, Eur J Cancer Clin Oncol, 1984, pp. 33-40.
Canetta et al.,Megestrol Acetate, Cancer Treatment Reviews, vol. 10, 1983, pp. 141-157.
Whitehead et al.,Actions of Progestins on the Morphology and Biochemistry of the Endometrium of Postmenopausal Women Receiving Low-Dose Estrogen Therapy, Am. M. Obstet. Gynecol. vol. 142, No. 6, Mar. 15, 1982, pp. 791-795.
Megestrol Acetate, LARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol. 21, 1979, pp. 431-439.
Donkervoort et al.,Megestrol Acetate in Treatment of Benign Prostatic Hypertrophy, Urology, vol. VI, No. 5, Nov. 1975, pp. 580-587.
Tisell et al.,Androgenic Properties and Adrenal Depressant Activity of Megestrol Acetate Observed in Castrated Male Rats, Acta Endocrinologica, vol. 78, 1975, pp. 316-324.
Burke et al.,Megestrol Acetate for Estrus Postponement in the Bitch, JAVMA, vol. 167, No. 4, pp. 285-287.
Wait,Megestrol Acetate in the Management of Advanced Endometrial Carcinoma, Obstetrics and Gynecology, vol. 41, No. 1, Jan. 1973, pp. 129-136.
Balin et al.,Low Dosage Megestrol Acetate Application as Contraceptive, The Journal of Reproductive Medicine, vol. V, No. 1, Jul. 1979, pp. 74-81.
Cooper et al.,The Metabolism of Megestrol Acetate(17 ∀-Acetoxy-6-Methylpregna-4,6-Diene-3,20-Dione)in Women, Steroids, vol. 11, No. 2, Feb. 1968, pp. 133-149.
International Search Report corresponding to PCT/US 02/15690 mailed on May 12, 2002.
O'Connor, Vivenne M. “Managing Menopause: Part 2: what are the choices in treatment?”MedicineTodaypp. 30-40 Feb. 2001.
David et al.,Anti-Ovulatory and Other Biological Properties of Megestrol Acetate 17 ∀-Acetoxy-6 Methyl Pregna 4:6-Diene-3:20-Dione(B.D.H. 1298). J. Reprod. Fertil., vol. 5, 1963, pp. 331-346.
Office Action corresponding to Canadian Patent Application No. 2,446,849 dated Apr. 20, 2011.
Davis et al. “Androgen Replacement in Women”,Contemporary Endocrinology Hormone Replacement TherapyChapter 22:401-417 (1999).
Examination Report corresponding to European Application No. 02736946.1 dated Jun. 29, 2011.
Wentz “Progestin Therapy in Endometrial Hyperplasia”,Gynecologic Oncology2:362-367 (1974).
Barr Laboratories, Inc.
Henley III Raymond
Myers Bigel & Sibley Sajovec, PA
LandOfFree
Treatment of conditions relating to hormone deficiencies by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of conditions relating to hormone deficiencies by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of conditions relating to hormone deficiencies by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298688